Antitumor activity of novel reversible LSD1 inhibitors in preclinical models of AML and SCLC.

被引：0
|
作者：
Byun, Joo-Yun [1 ]
Lee, Won Jong [1 ]
Kim, Won jung [1 ]
Kim, Minjeong [1 ]
Bae, Inhwan [1 ]
Hong, Seokhyun [1 ]
Kim, Yu-Yon [1 ]
Park, Hyunjin [1 ]
Kim, Eunyoung [1 ]
Kim, Young Hoon [1 ]
Ahn, Young Gil [1 ]
Suh, Kwee Hyun [1 ]
机构：
[1] Hanmi Res Ctr, Hwaseong Si, South Korea
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1135
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Design and identification of two novel resveratrol derivatives as potential LSD1 inhibitors
    Xu, Yongtao
    Gao, Yunlong
    Yang, Min
    Wang, Meiting
    Lu, Jiarui
    Wu, Ziqing
    Zhao, Junqiang
    Yu, Yi
    Wang, Chang
    Zhao, Zongya
    Gao, Qinghe
    Duan, Yingchao
    Han, Di
    FUTURE MEDICINAL CHEMISTRY, 2021, 13 (17) : 1415 - 1433
  • [32] Novel colorimetric assay of LSD1 activity using gold nanoparticles
    Piao, Jing Yu
    Chung, Doo Soo
    ANALYST, 2012, 137 (11) : 2669 - 2673
  • [33] Identification of novel indole derivatives as highly potent and efficacious LSD1 inhibitors
    Zhang, Xiangyu
    Sun, Yixiang
    Huang, Hailan
    Wang, Xinran
    Wu, Tianxiao
    Yin, Wenbo
    Li, Xiaojia
    Wang, Lin
    Gu, Yanting
    Zhao, Dongmei
    Cheng, Maosheng
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 239
  • [34] Design, synthesis, and biological evaluation of coumarin analogs as novel LSD1 inhibitors
    Sun, Yixiang
    Lv, Ruicheng
    Wu, Tianxiao
    Zhang, Xiangyu
    Sun, Yin
    Yan, Jiangkun
    Zhang, Ziheng
    Zhao, Dongmei
    Cheng, Maosheng
    ARCHIV DER PHARMAZIE, 2022, 355 (02)
  • [35] Novel anti-tumor activity of targeted LSD1 inhibition
    Kruger, Ryan G.
    CANCER RESEARCH, 2014, 74 (19)
  • [36] Discovery of Pyrrolo[2,3-c]pyridines as Potent and Reversible LSD1 Inhibitors
    Zheng, Canhui
    Rej, Rohan Kalyan
    Wang, Mi
    Huang, Liyue
    Fernandez-Salas, Ester
    Yang, Chao-Yie
    Wang, Shaomeng
    ACS MEDICINAL CHEMISTRY LETTERS, 2023, : 1389 - 1395
  • [37] Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models
    Jasmine, Sumer
    Mandl, Adel
    Krueger, Timothy E. G.
    Dalrymple, Susan L.
    Antony, Lizamma
    Dias, Jennifer
    Celatka, Cassandra A.
    Tapper, Amy E.
    Kleppe, Maria
    Kanayama, Mayuko
    Jing, Yuezhou
    Speranzini, Valentina
    Wang, Yuzhuo Z.
    Luo, Jun
    Trock, Bruce J.
    Denmeade, Samuel R.
    Carducci, Michael A.
    Mattevi, Andrea
    Rienhoff Jr, Hugh Y.
    Isaacs, John T.
    Brennen, W. Nathaniel
    PROSTATE, 2024, 84 (10): : 909 - 921
  • [38] Design, synthesis and biological activity of N-(3-substituted-phenyl)benzenesulfonamides as selective and reversible LSD1 inhibitors
    Xiaoming Zha
    Liming Wu
    Siyuan Xu
    Fangxia Zou
    Jiayue Xi
    Tianfang Ma
    Rongfeng Liu
    Yu-Chih Liu
    Dawei Deng
    Yueqing Gu
    Jinpei Zhou
    Fei Lan
    Medicinal Chemistry Research, 2016, 25 : 2822 - 2831
  • [39] Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors
    Duan, Yingchao
    Yu, Tong
    Jin, Linfeng
    Zhang, Shaojie
    Shi, Xiaojing
    Zhang, Yizhe
    Zhou, Nanqian
    Xu, Yongtao
    Lu, Wenfeng
    Zhou, Huimin
    Zhu, Huijuan
    Bai, Suping
    Hu, Kua
    Guan, Yuanyuan
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 254
  • [40] Characterizing antitumor responses to EXS-74539, a novel, reversible LSD1 inhibitor with potential in small-cell lung cancer
    Payne, Andrew
    Naik, Manisha
    Richards, Simon
    Perez, Victor Sebastian
    Dominguez, Maria
    CANCER RESEARCH, 2023, 83 (07)
12345